XBiotech Inc.
Close on Oct 19, 2026
- Market cap
- $60.98M
- P/E (TTM)
- –
- Dividend yield
- –
About XBiotech
Pharmaceutical Preparations, SIC 2834
XBiotech Inc. is a biopharmaceutical company focused on discovering and developing True Human monoclonal antibodies to treat various diseases. These antibodies are sourced from human donors exhibiting natural immune responses rather than through animal engineering methods. The company focuses on developing antibody therapies that neutralize interleukin-1 alpha, a protein involved in inflammatory tissue breakdown, trauma response, and disease processes. Its clinical and research pipeline includes candidates for conditions in oncology, rheumatology, neurology, and infectious diseases such as methicillin-resistant Staphylococcus aureus, shingles, influenza, and Clostridioides difficile.
The company operates an integrated research and manufacturing campus situated on 48 acres in Austin, Texas, where it conducts laboratory research, clinical trial development, and drug substance production. As of December 31, 2025, XBiotech employed 85 full-time personnel across its administrative, research, and manufacturing operations. The company maintains its principal executive offices in Austin, Texas.
Summary of the business section of XBiotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- XBiotech Inc.
- Founded
- 2005
- Headquarters
- Austin, TX
- Address
- 5217 Winnebago Lane 78744
- Phone
- (512) 386-2900
- Website
- xbiotech.com
- Employees
- 85, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- Whitley Penn LLP, Austin, Texas
Stock & identifiers
- Ticker
- XBIT
- Exchange
- Nasdaq
- IPO date
- Apr 16, 2015
- Shares outstanding
- 30M, Aug 13, 2026
- Public float
- $77.05M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1626878
- CUSIP
- 98400H102
- ISIN
- US98400H1023
- LEI
- 5299002WACAY28TQAS52
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Simard | Chief Executive Officer, Director | 3,823,166 |
| David Spencer Soffer | Director | – |
| Thomas Martin Kuendig | Director | 300,000 |
| Tevi David Troy | Director | – |
| Craig Evan Rademaker | Director | 170,985 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Mr. Simard | $6.25M | $6.25M | $471.50K | $2 | – |
| FY2023 Mr. Simard | $5.56M | $5.56M | $499.89K | $14 | – |
| FY2022 Mr. Simard | $4.67M | $4.67M | $356.75K | $-69 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 85 total full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 7, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 13, 2022 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 30, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 19, 2018 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 16, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 14, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |